ELEDON PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.31 USD | -3.75% |
|
-4.15% | +28.33% |
Presentation Operator MessageOperator (Operator)Good day, and welcome to the Eledon Pharmaceut...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Companyâs lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
Calendar
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.31
USD
Average target price
14
USD
Spread / Average Target
+506.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +28.33% | 57.32M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- ELDN Stock
- News Eledon Pharmaceuticals, Inc.
- Transcript : Eledon Pharmaceuticals, Inc., Q3 2022 Earnings Call, Nov 14, 2022
